Steroid biosynthesis and prostate cancer
- 1 June 2012
- journal article
- review article
- Published by Elsevier BV in Steroids
- Vol. 77 (7), 719-726
- https://doi.org/10.1016/j.steroids.2012.03.015
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancerProceedings of the National Academy of Sciences, 2011
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic ResponseClinical Cancer Research, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate CancerCancer Research, 2011
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Phase II Study of Dutasteride for Recurrent Prostate Cancer During Androgen Deprivation TherapyJournal of Urology, 2009
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy ResistanceCancer Research, 2008
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990